Immuneed Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
26
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
5
Immuneed General Information
Description
Operator of a contract research organization intended to research and develop therapeutic cancer vaccine drugs. The company's contract research organization specializes in services for immunotoxicology and immunophenotyping based on human whole-blood assay with a specific focus on monoclonal antibodies, thereby enabling medical institutions and health organizations to supply them with an optimum patent-pending idea that will enhance both peptide uptake and cellular immune activation.
Contact Information
Website
www.immuneed.com(Operating Subsidiary)
Corporate Office
- Kungsgatan 70 D
- 753 41 Uppsala
- Sweden
Corporate Office
- Kungsgatan 70 D
- 753 41 Uppsala
- Sweden
Immuneed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immuneed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immuneed Patents
Immuneed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016071890-A1 | Theranostic method for optimizing the choice of an immune checkpoint blocker to be administered to a cancer patient | Inactive | 07-Nov-2014 | ||
| WO-2016009415-A1 | Use of immune diversity as a predictive marker for identifying b-cell-lymphomas-patients having an increased risk of febrile or infectious event | Inactive | 18-Jul-2014 | ||
| WO-2015162596-A1 | Use of immune diversity as a predictive marker for identifying patients likely to respond to an anti-ctla4 treatment | Inactive | 25-Apr-2014 | ||
| WO-2011070256-A1 | Use of the combinatorial diversity of t-lymphocyte repertoire as a prognostic marker of cancer | Inactive | 09-Dec-2009 | ||
| EP-2333106-A1 | Use of the combinatory diversity of the catalogue of t lymphocytes as a cancer prognostic marker | Inactive | 09-Dec-2009 | C12Q1/6886 |
Immuneed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immuneed Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immuneed FAQs
-
When was Immuneed founded?
Immuneed was founded in 2014.
-
Where is Immuneed headquartered?
Immuneed is headquartered in Uppsala, Sweden.
-
What is the size of Immuneed?
Immuneed has 26 total employees.
-
What industry is Immuneed in?
Immuneed’s primary industry is Drug Discovery.
-
Is Immuneed a private or public company?
Immuneed is a Private company.
-
What is the current valuation of Immuneed?
The current valuation of Immuneed is .
-
What is Immuneed’s current revenue?
The current revenue for Immuneed is .
-
How much funding has Immuneed raised over time?
Immuneed has raised $507K.
-
Who are Immuneed’s investors?
Almi Invest, STUNS Life Science, STW Valorisation Grant, Swedish Society for Medical Research, and Uppsala Akademiförvaltning have invested in Immuneed.
-
When was Immuneed acquired?
Immuneed was acquired on 11-Jul-2018.
-
Who acquired Immuneed?
Immuneed was acquired by Ultimovacs.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
